Toremifene: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: February 27, 2026🚩 Report this page

Toremifene

Anti-Estrogens

Sold as Fareston

GB MHRAEU EMA

Drug class: Anti-Estrogens
Availability: See label
Markets covered: 2
Products on record: 2

Overview

Toremifene is an active pharmaceutical ingredient in the Anti-Estrogens group (L02BA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	February 27, 2026
EU European Union	EMA	1	July 30, 2024

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised February 27, 2026[1]

First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Fareston is not recommended for patients with estrogen receptor negative tumours.

How to take

EUEuropean Union· EMA

1 product

Uses

EUOfficial regulatory label· revised July 30, 2024[2]

First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Fareston is not recommended for patients with estrogen receptor negative tumours.

How to take

Drug interactions

Known interactions involving Toremifene. Select one for details. This list is informational and not a complete interaction checker.

Abarelix Abiraterone Adenosine Alfuzosin Amiodarone Amisulpride Amitriptyline Amoxapine Amprenavir Anagrelide Apalutamide Apomorphine Arsenic Trioxide Asenapine Astemizole Atazanavir Atomoxetine Azithromycin Bedaquiline Bepridil Bicalutamide Boceprevir Bosutinib Buprenorphine Cabozantinib Carbamazepine Carfilzomib Ceritinib Chloroquine Chlorpromazine Cilostazol Ciprofloxacin Cisapride Citalopram Clarithromycin Clofazimine Clomipramine Clozapine Cobicistat Conivaptan Crizotinib Dasatinib Daunorubicin Degarelix Delavirdine Desipramine Deutetrabenazine Dexamethasone Disopyramide Dofetilide Dolasetron Doxepin Doxorubicin Dronedarone Droperidol Efavirenz Encorafenib Entrectinib Enzalutamide Epirubicin Eribulin Erythromycin Escitalopram Ezogabine Fingolimod Flecainide Fluconazole Fluoxetine Fluphenazine Flutamide Fosamprenavir Foscarnet Fosphenytoin Fostemsavir Gatifloxacin Gemifloxacin Gilteritinib Glasdegib Goserelin Granisetron Grepafloxacin Halofantrine Haloperidol Halothane Histrelin Hydroxychloroquine Hydroxyzine Ibutilide Idarubicin Idelalisib Iloperidone Imipramine Indinavir Inotuzumab Ozogamicin Isoproterenol Itraconazole Ivabradine Ivosidenib Ketoconazole Lapatinib Lefamulin Lenalidomide Lenvatinib Leuprolide Levofloxacin Lisdexamfetamine Lithium Carbonate Lofexidine Lomefloxacin Lonafarnib Lumacaftor Lumefantrine Macimorelin Maprotiline Mefloquine Mesoridazine Metaproterenol Methadone Methotrimeprazine Midostaurin Mifepristone Mirtazapine Mitotane Moxifloxacin Nefazodone Nelfinavir Nilotinib Nilutamide Norfloxacin Nortriptyline Ofloxacin Oliceridine Ondansetron Osilodrostat Osimertinib Oxaliplatin Oxytocin Ozanimod Paliperidone Palonosetron Panobinostat Papaverine Pasireotide Pazopanib Pentamidine Perflutren Perphenazine Phenobarbital Phenytoin Picosulfurate Pimavanserin Pimozide Pitolisant Pomalidomide Posaconazole Primaquine Primidone Probucol Procainamide Prochlorperazine Promazine Promethazine Propafenone Propoxyphene Protriptyline Quetiapine Quinidine Quinine Ranolazine Relugolix Ribociclib Rifabutin Rifampin Rifapentine Rilpivirine Risperidone Ritodrine Ritonavir Romidepsin Rucaparib Saquinavir Selpercatinib Sertraline Sevoflurane Siponimod Sodium Sulfate Solifenacin Sorafenib Sotalol Sparfloxacin Sunitinib Tacrolimus Tamoxifen Telaprevir Telavancin Telithromycin Terbutaline Terfenadine Tetrabenazine Thalidomide Thioridazine Tizanidine Tramadol Tranexamic Acid Trazodone Triclabendazole Trifluoperazine Triflupromazine Trimeprazine Trimipramine Triptorelin Troleandomycin Tucatinib Valbenazine Vandetanib Vardenafil Vemurafenib Venlafaxine Voriconazole Ziprasidone Abametapir Albuterol Aminoglutethimide Amobarbital Anisindione Aprepitant Arformoterol Aripiprazole Armodafinil Bendroflumethiazide Benzthiazide Berotralstat Bexarotene Bisacodyl Bosentan Brigatinib Butabarbital Butalbital Castor Oil Cenobamate

Showing 240 of 338. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PLGB279250106 · revised February 27, 2026
[2]European Medicines Agency · EMEA/H/C/000091 · revised July 30, 2024

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised February 27, 2026[1]

The most frequent adverse reactions are hot flushes, sweating, uterine bleeding, leukorrhea, fatigue, nausea, rash, itching, dizziness and depression. The reactions are usually mild and mostly due to thehormonal action of toremifene.
The frequencies of the adverse reactions are classified as follows:
Very common (≥ 1/10) Common (≥ 1/100 to <1/10) Uncommon (≥ 1/1,000 to < 1/100) Rare (≥ 1/10 000 to < 1/1 000) Very rare (< 1/10 000), not known (cannot be estimated from the available data). 4). Toremifene treatment has been associated with changes in liver enzyme levels (increases of transaminases) and in very rare occasions with more severe liver function abnormalities (jaundice).
A few cases of hypercalcaemia have been reported in patients with bone metastases at the beginning of toremifene treatment. Endometrial hypertrophy may develop during the treatment due to the partial estrogenic effect of toremifene.
There is a risk of increased endometrial changes including hyperplasia, polyps and cancer. 4). 4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised February 27, 2026[1]

Gynaecological examination should be performed before treatment administration, closely looking at pre-existing endometrial abnormality. Afterwards gynaecological examination should be repeated at least once a year. g. 8). Anemia, leukopenia and thrombocytopenia have been reported.
Red blood cell, leukocyte or platelet counts should be monitored when using Fareston. Cases of liver injury, including elevation of liver enzymes (> 10 times upper limit of normal), hepatitis and jaundice have been reported with toremifene.
Most of them occurred during the first months of treatment. The pattern of the liver damage was predominantly hepatocellular. 8). Fareston has been shown to prolong the QTc interval on the electrocardiogram in some patients in a dose-related manner.
3). A QT clinical study with a 5-arm parallel design (placebo, moxifloxacin 400 mg, toremifene 20 mg, 80 mg, and 300 mg) has been performed in 250 male patients to characterize the effects of toremifene on the QTc interval duration.
The results of this study show a clear positive effect of toremifene in the 80 mg group with mean prolongations of 21–26 ms. Regarding the 20 mg group, this effect is significant as well, according to ICH guidelines, with upper confidence interval of 10–12 ms.
These results strongly suggest an important dose- dependent effect. As women tend to have a longer baseline QTc interval compared with men, they may be more sensitive to QTc-prolonging medications. Elderly patients may also be more susceptible to drug-associated effects on the QT interval.
Fareston should be used with caution in patients with ongoing proarrhythmic conditions (especially elderly patients) such as acute myocardial ischaemia or QT prolongation as this may lead to an increased risk for ventricular arrhythmias (incl.
3). If signs or symptoms that may be associated with cardiac arrhythmia occur during treatment with Fareston, treatment should be stopped and an ECG should be performed. If the QTc interval is > 500 ms, Fareston should not be used. Patients with non-compensated cardiac insufficiency or severe angina pectoris should be closely monitored.
Hypercalcemia may occur at the beginning of toremifene treatment in patients with bone metastasis and thus these patients should be closely monitored. There are no systematic data available from patients with labile diabetes, from patients with severely altered performance status or from patients with cardiac failure.
Excipients Fareston tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. This medicinal product contains less than 1 mmol (23 mg) sodium per dosage unit, that is to say essentially ‘sodium-free’.

This is not medical advice. Consult a qualified healthcare professional.